Literature DB >> 27016200

[Procedure for daylight methyl aminolevulinate photodynamic therapy to treat actinic keratoses].

C Girard1, H Adamski2, N Basset-Séguin3, P Beaulieu4, B Dreno5, J-L Riboulet6, J-P Lacour7.   

Abstract

Actinic keratosis (AK), also known as solar keratosis or pre-cancerous keratosis, is frequently observed in areas of skin exposed to sunlight, particularly in light-skinned patients. In France, photodynamic therapy using red light (conventional PDT) and methylamino 5-levulinate (MAL) is indicated in the treatment of thin or non-hyperkeratotic and non-pigmented multiple AK lesions or large zones covered with AK lesions. It is well-known for its efficacy but also for its side effects, especially pain during illumination, which can limit its use. An alternative to PDT using natural daylight has recently been proposed to treat actinic keratosis lesions, and results in greater flexibility as well as significant reduction in pain. The lesions are prepared as for conventional PDT, with MAL cream being applied by the physician or the patient, after which they are exposed to natural daylight for 2hours. The lesions are then gently cleansed and protected from natural light for 24hours. This paper seeks to provide a precise description of the daylight PDT procedure for the treatment of AK.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Actinic keratosis; Aminolévulinate de méthyle; Daylight; Kératoses actiniques; Lumière du jour; Methyl aminolevulinate; Photodynamic therapy; Photothérapie dynamique topique

Mesh:

Substances:

Year:  2016        PMID: 27016200     DOI: 10.1016/j.annder.2016.02.016

Source DB:  PubMed          Journal:  Ann Dermatol Venereol        ISSN: 0151-9638            Impact factor:   0.777


  1 in total

1.  MAL Daylight Photodynamic Therapy for Actinic Keratosis: Clinical and Imaging Evaluation by 3D Camera.

Authors:  Carmen Cantisani; Giovanni Paolino; Giovanni Pellacani; Dario Didona; Marco Scarno; Valentina Faina; Tommaso Gobello; Stefano Calvieri
Journal:  Int J Mol Sci       Date:  2016-07-11       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.